Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
Overall IDP gets a fundamental rating of 6 out of 10. We evaluated IDP against 86 industry peers in the Biotechnology industry. IDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IDP has a bad growth rate and is valued cheaply. With these ratings, IDP could be worth investigating further for value investing!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.28 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.21 | ||
| Fwd PE | 11.06 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.09 | ||
| EV/EBITDA | 7.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.